Drug Profile


Alternative Names: IZN-6D4

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Izun Pharma
  • Class Antiulcers; Herbal medicines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer

Most Recent Events

  • 13 Oct 2015 Efficacy data from a phase-II trial in Diabetic foot ulcer released by Izun Pharma
  • 17 Aug 2015 Phase-II development for Diabetic foot ulcer is ongoing in Israel
  • 01 Aug 2015 Izun Pharma completes a phase II trial in Diabetic foot ulcer in Israel (Topical) (NCT01427569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top